Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate
- Conditions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00093639
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT00093600
- Locations
- 🇺🇸
Dana Faber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT00088595
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Louisiana State University Medical Center, New Orleans, Louisiana, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
- Conditions
- Interventions
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT00088582
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Michigan Medical Center, Ann Arbor, Michigan, United States
🇺🇸New York University/VA Medical Center, New York, New York, United States
A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
- Conditions
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT00088608
- Locations
- 🇺🇸
Midwest Endocrinology Associates, Milwaukee, Wisconsin, United States
🇺🇸Cedars-Sinai Pituitary Center, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital NE Unit, Boston, Massachusetts, United States
A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy
- Conditions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00087659
- Locations
- 🇺🇸
Veterans Affairs Medical Center, Augusta, Georgia, United States
🇺🇸WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina, United States
🇺🇸West Sde Vamc, Chicago, Illinois, United States
Non-small Cell Lung Cancer Study US75 (Z-PACT)
- Conditions
- Interventions
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 250
- Registration Number
- NCT00086268
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Advocate Illinois Masonic Medical Center Creticos Cancer Center, Chicago, Illinois, United States
🇺🇸Central Indiana Cancer Centers, Indianapolis, Indiana, United States
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
- Conditions
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 544
- Registration Number
- NCT00005073
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia
- Conditions
- First Posted Date
- 2004-06-08
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2136
- Registration Number
- NCT00084071
- Locations
- 🇧🇷
Belgium, Salvador, BA, Brazil
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT00081926
- Locations
- 🇺🇸
Novartis RIGHT Trial Hotline, East Hanover, New Jersey, United States